.png)
（ 母液浓度为 40 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们客服联系。| 中文名称: | 唑喹达三盐酸盐 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | Zosuquidar trihydrochloride | ||||
| 别名: | 唑喹达三盐酸盐 RS33295-198trihydrochloride;LY-335979trihydrochloride | ||||
| CAS No: | 167465-36-3 | 分子式: | C32H31F2N3O2.3HCl | 分子量: | 636.99 |
| CAS No: | 167465-36-3 | ||||
| 分子式: | C32H31F2N3O2.3HCl | ||||
| 分子量: | 636.99 | ||||
包装规格：
5mg 10mg 50mg in glass bottle
溶解性：
溶于DMSO(1mg/ml超声）水(5mg/ml超声)
产品描述：
基本信息
|
产品编号： |
Z10081 |
||||
|
产品名称： |
Zosuquidar trihydrochloride |
||||
|
CAS: |
167465-36-3 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
4℃ |
二年 |
||||
|
分子式： |
|||||
|
分子量： |
636.99 |
||||
|
化学名： |
(R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol,trihydrochloride |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
1.5699mL |
7.8494mL |
15.6988mL |
|
5mM |
0.3140mL |
1.5699mL |
3.1398mL |
生物活性
|
产品描述 |
P-糖蛋白(P-glycoprotein)抑制剂，Ki值为59nM。 |
|
靶点 |
Ki:59nM (P-glycoprotein). |
|
体外研究 |
Zosuquidar completely or partially restores drug sensitivity in all P-gp-expressing leukemia cell lines and enhances the cytotoxicity of anthracyclines (daunorubicin,idarubicin,mitoxantrone) and gemtuzumab ozogamicin (Mylotarg) in primary AmL blasts with active P-gp.In addition,P-gp inhibition by zosuquidar is found to be more potent than cyclosporine A in cells with highly active P-gp. |
|
体内研究 |
Zosuquidar trihydrochloride is only moderately active as an inhibitor of P-gp at the blood-brain.An oral dose of 25mg/kg of zosuquidar trihydrochloride increases the brain concentrations by about 2.5-fold at 1h and 5-fold at 24h after paclitaxel administrationbarrier.Zosuquidar enhances the brain uptake of nelfinavir in a dose-dependent manner.Brain tissue/plasma nelfinavir concentration ratios increase from 0.06±0.03 in the absence of zosuquidar administration and 0.09±0.02 between 2 and 6h after a 2mg/kg intravenous dose of zosuquidar to 0.85±0.19 after 6h and 1.58±0.67 after 20mg/kg zosuquidar. |
推荐实验方法(仅供参考)
|
细胞实验: |
|
|
Cells are cultured in 96-well plates. Each drug of interest is added at escalating concentrations in the presence or absence of either zosuquidar or CsA.After 48 hour incubation (except Mylotarg,4 days incubation),20μL of MTT is added to each well for a further 4 hour incubation.The purple precipitate is dissolved in 200μL DMSO,and the optic density (OD) is determined by the multi-well plate reader. |
|
|
动物实验: |
|
|
Rats:Female Sprague-Dawley rats are used in the study.Zosuquidar solutions are prepared in 5% mannitol and adjusted to pH 〜2.0 with concentrated HCl.Nelfinavir is infused (10mg/kg/h) for up to 10h with or without concurrent administration of an intravenous bolus dose of 2,6,or 20mg/kg zosuquidar given at 4h.Brain tissue and plasma are analyzed for both drug concentrations.
Mice:A stock solution of 5mg/mL of zosuquidar trihydrochloride is prepared in vehicle solution and diluted in sterile saline.The vehicle solution consisted of 20g/l mannitol and 1.5g/l of glycine in water for injection and adjusted to a pH of 2.7 with hydrochloric acid.P-gp knockout mice and wild type mice are used as a model for complete inhibition of P-gp.Zosuquidar trihydrochloride is administered orally at 25 and 80mg/kg 1h before i.v.paclitaxel and i.v.at 20mg/kg 10 min and 1h before paclitaxel.The concentrations of paclitaxel in plasma and tissues and of zosuquidar trihydrochloride in plasma are quantified by high-performance liquid chromatography. |
|
保存条件：
-20℃
UN码：
HazardClass：
危害声明：
安全说明：
搜索质检报告(COA)
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
(2).jpg)
体内配方的制备方法: 取 50μLDMSO 母液，添加 300 μLPEG300 混匀澄清，再加 50μLTween80, 混匀澄清，再加 600μLSaline/PBS/ddH2O 混匀澄清
方案所需的各种助溶剂如： DMSO ， PEG300 / PEG400 ， Tween 80 ， SBE-β-CD ， 玉米油 等， 均可点击跳转或在网站搜索购买。
母液，添加 300 μLPEG300 混匀澄清，再加 50μLTween80, 混匀澄清，再加 600μLSaline/PBS/ddH2O 混匀澄清方案所需的各种助溶剂如： DMSO ， PEG300 / PEG400 ， Tween 80 ， SBE-β-CD ， 玉米油 等， 均可点击跳转或在网站搜索购买。
以上为“动物实验计算换算器”的使用方法举例，并不是具体某个试剂的配制，请根据您的实验动物和给药方式选择适当的溶解方案。
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL Saline/PBS/ddH2O，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
剂量转换
对于不同动物的给药剂量换算，您也可以参考 更多
